Oncology trial management demands a level of operational precision that separates generalist site networks from organizations built specifically for cancer research. Patient populations are medically complex, protocols are lengthy, dropout risk is high, and the regulatory bar for Phase I dose-escalation studies is unforgiving. Sponsors and CROs selecting partners for oncology programs need more than site count \u2014 they need community access, Phase I infrastructure, and a track record in diverse patient populations.<\/p>\n
This guide outlines what distinguishes high-performing oncology trial management organizations in 2025, and what sponsors should evaluate before committing to a site network for their oncology program.<\/p>\n
<\/p>\n
Oncology studies operate under constraints that do not apply to most other therapeutic areas.<\/p>\n
Patient eligibility is narrow.<\/strong> Inclusion and exclusion criteria in oncology protocols are among the most restrictive in clinical research. Sites without established oncology patient pipelines will screen hundreds of candidates to enroll a handful. This makes community access \u2014 not just site infrastructure \u2014 the primary enrollment driver.<\/p>\n Phase I requires dedicated infrastructure.<\/strong> First-in-human and dose-escalation studies require specialized facilities, experienced investigators, enhanced safety monitoring protocols, and proximity to emergency care. Not every site network can support Phase I oncology \u2014 and sponsors who assume otherwise face costly activation delays.<\/p>\n Diverse enrollment is a scientific requirement.<\/strong> Cancer incidence, treatment response, and drug metabolism vary significantly across racial and ethnic groups. FDA’s guidance on diversity in oncology trials is increasingly prescriptive. Sites that cannot reach Black, Hispanic\/Latino, and other underrepresented populations produce data with limited generalizability \u2014 a problem that surfaces at the NDA stage.<\/p>\n Retention is harder.<\/strong> Oncology patients face significant treatment burden. Sites without bilingual coordinators, flexible scheduling, and community support infrastructure see higher dropout rates \u2014 particularly in long-duration studies.<\/p>\n <\/p>\n 1. Phase I capability<\/strong> Evaluate whether the organization operates dedicated Phase I units with trained staff, appropriate monitoring infrastructure, and established relationships with oncology specialists. Phase I oncology is not an add-on service \u2014 it requires purpose-built infrastructure.<\/p>\n 2. Community-embedded site footprint<\/strong> The strongest oncology trial management organizations have existing relationships with community health networks, cancer support organizations, and local providers before a protocol opens. This determines how quickly diverse patients can be identified and screened.<\/p>\n 3. Bilingual and culturally concordant staff<\/strong> Hispanic\/Latino and Black communities carry disproportionate cancer burden in several indications \u2014 including colorectal, cervical, and prostate cancer. Sites serving these communities need bilingual coordinators and investigators who reflect the patient population.<\/p>\n 4. Regulatory and safety track record<\/strong> Clean FDA inspection history is non-negotiable for Phase I oncology. Sponsors should request inspection records and review any observations related to safety reporting, protocol deviations, or informed consent.<\/p>\n 5. Therapeutic area depth<\/strong> Organizations with experience across multiple oncology indications \u2014 solid tumors, hematologic malignancies, immunotherapy \u2014 bring protocol familiarity that reduces activation time and coordinator training burden.<\/p>\n <\/p>\n FOMAT Medical is an embedded research organization operating across seven U.S. states \u2014 California, Texas, North Carolina, Maryland, Michigan, New Mexico, and Colorado \u2014 with a dedicated Phase I oncology unit in California.<\/p>\n Unlike generalist site networks that add oncology as an indication alongside dozens of others, FOMAT’s California Phase I unit was built specifically for oncology research. The infrastructure, staffing, and investigator relationships reflect the demands of dose-escalation studies and first-in-human protocols \u2014 not repurposed from a general medicine setting.<\/p>\n <\/p>\n FOMAT’s embedded model means patient access in oncology does not depend on advertising campaigns. Through established partnerships with community health organizations and local care networks in California, FOMAT reaches patient populations \u2014 including Hispanic\/Latino and other underrepresented communities \u2014 who are chronically underenrolled in oncology trials.<\/p>\n This community integration is structural, not tactical. Referral pathways, patient education programs, and bilingual outreach operate continuously across the network \u2014 not only when a protocol is open.<\/p>\n <\/p>\n Most oncology trial management organizations recruit patients. An embedded research organization is already present in the communities where those patients live and receive care. The distinction matters because:<\/p>\n <\/p>\n Phase I oncology infrastructure.<\/strong> Dedicated unit in California with experienced investigators and safety monitoring protocols designed for dose-escalation studies.<\/p>\n Bilingual operations.<\/strong> Spanish-English bilingual staff across the network, with patient-facing materials available in both languages.<\/p>\n Multi-state reach.<\/strong> Seven states providing geographic diversity for Phase II and Phase III expansion following Phase I completion at a single site.<\/p>\n Regulatory track record.<\/strong> Clean FDA inspection history across the network, with experience in the oversight requirements for NDA-enabling oncology studies.<\/p>\n Phase I through IV continuity.<\/strong> Sponsors who initiate Phase I at FOMAT’s California unit can expand to the broader network for later-phase studies without requalifying a new partner.<\/p>\n <\/p>\n What is oncology trial management?<\/strong> Oncology trial management refers to the operational oversight of clinical studies in cancer research \u2014 including site activation, patient recruitment, protocol compliance, safety monitoring, and data management. Organizations specializing in oncology trial management provide infrastructure and expertise specific to the complexity of cancer studies, from Phase I dose-escalation through Phase III pivotal trials.<\/p>\n What makes Phase I oncology trials different from other Phase I studies?<\/strong> Phase I oncology trials \u2014 particularly first-in-human and dose-escalation studies \u2014 require specialized safety monitoring, experienced investigators with oncology backgrounds, proximity to emergency care, and enhanced informed consent protocols. The patient population is typically more medically complex than in other therapeutic areas, and the regulatory requirements for safety reporting are more stringent.<\/p>\n Why is diverse patient enrollment important in oncology research?<\/strong> Cancer incidence, progression, and treatment response vary across racial and ethnic groups. Enrolling diverse patient populations ensures that efficacy and safety data reflect the populations who will ultimately use the therapy. FDA guidance increasingly requires sponsors to demonstrate diversity in oncology trial enrollment, including submission of Diversity Action Plans<\/a> for certain studies.<\/p>\n5 Criteria for Evaluating Oncology Trial Management Organizations<\/strong><\/h3>\n
FOMAT: Oncology Trial Management with Phase I Infrastructure and Community Reach<\/strong><\/h3>\n
Community access through local partnerships<\/strong><\/h3>\n
What the embedded model delivers in oncology<\/strong><\/h3>\n
\n
Network capabilities relevant to oncology sponsors<\/strong><\/h3>\n
Frequently Asked Questions<\/strong><\/h3>\n